Page last updated: 2024-12-09
zln005
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ZLN005: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 899323 |
| CHEMBL ID | 4303368 |
| SCHEMBL ID | 6755306 |
| MeSH ID | M0584887 |
Synonyms (38)
| Synonym |
|---|
| CBMICRO_034305 |
| 4529-96-8 |
| BIM-0034399.P001 |
| STK395157 |
| 2-(4-tert-butylphenyl)-1h-benzimidazole |
| AKOS003029495 |
| 49671-76-3 |
| S7447 |
| HY-17538 |
| zln005 |
| 2-(4-(tert-butyl)phenyl)-1h-benzo[d]imidazole |
| SCHEMBL6755306 |
| AC-35224 |
| 2-(4-tert-butylphenyl)-1h-benzo[d]imidazole |
| zln 005 |
| 2-(4-tert-butylphenyl)-1h-1,3-benzodiazole |
| (1s,2r,3r,5s,6s,16e,18e,20r,21s)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracycl o[19.3.1.110,14.03,5]hexacosa-10(26),11,13,16,18-pentaen-6-yl 2- methylpropanoate |
| J-690308 |
| EX-A690 |
| DTXSID60358473 |
| HMS3653P03 |
| mfcd01560221 |
| NCGC00371152-01 |
| SW219815-1 |
| FT-0700319 |
| 2-(4-t-butylphenyl) benzimidazole |
| BCP08848 |
| zln-005 pound>>zln 005 |
| A13734 |
| CCG-266970 |
| CHEMBL4303368 |
| AS-55878 |
| A871757 |
| ZBA67176 |
| 2-(4-tert-butylphenyl)benzimidazole |
| 3WT26285WB |
| tqs-168 |
| zln-005 |
Research Excerpts
Treatment
ZLN005 treatment upregulated the expressions of PGC-1α and mitochondrial function-related genes in hESC-CMs. It induced more mature energy metabolism compared with the control group.
| Excerpt | Reference | Relevance |
|---|---|---|
| "ZLN005 treatment upregulated the expressions of PGC-1α and mitochondrial function-related genes in hESC-CMs and induced more mature energy metabolism compared with the control group." | ( PGC-1α activator ZLN005 promotes maturation of cardiomyocytes derived from human embryonic stem cells. Bai, H; Feng, X; Guo, F; Guo, J; Liang, P; Liu, Y; Lu, X; Luo, X; Thai, PN; Xu, Z; Yang, C; Yang, H; Zhang, P; Zhu, D, 2020) | 1.62 |
| "ZLN005 treatment led to ameliorated cardiomyocyte oxidative injury, enhanced cell viability, and reduced apoptosis in the high glucose environment." | ( ZLN005 protects cardiomyocytes against high glucose-induced cytotoxicity by promoting SIRT1 expression and autophagy. Chen, Y; Li, W; Li, X; Ou, D; Wang, B; Xiao, A; Yan, S; Zeng, D; Zheng, Q, 2016) | 2.6 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 26.68
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.68) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||